Replacement therapy for Addison's disease: recent developments
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The hormone deficiencies in Addison's disease (primary adrenal insufficiency) are conventionally treated with oral glucocorticoid and mineralocorticoid replacement but the available therapies do not restore the physiological hormone levels and biorhythm. Despite such treatment these patients self-report impaired health-related quality of life (HRQoL) and recent research has indicated increased mortality. OBJECTIVE/METHODS: We review the literature and recent developments in replacement therapy. RESULTS/CONCLUSION: Patients with Addison's disease require mineralocorticoid replacement, i.e., fludrocortisone 0.05 - 0.20 mg once daily. Starting doses of glucocorticoids should be 15 - 20 mg for hydrocortisone or 20 - 30 mg for cortisone acetate, divided into two or three doses, and preferentially weight-adjusted. There are indications that the synthetic glucocorticoids have undesirable metabolic long-term effects, which make them less suitable as first-line treatment. Timed-release hydrocortisone tablets and continuous subcutaneous hydrocortisone infusion are promising new treatment modalities. Studies of replacement with the adrenal androgen dehydroepiandrosterone (DHEA) in adrenal failure have shown inconsistent benefit on HRQoL. DHEA, or possibly testosterone replacement is likely to be beneficial for selected groups of patients with Addison's disease but this remains to be shown. We here give our opinion of the best treatment and future direction of research in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“The GR is a nuclear receptor that is ubiquitously expressed in all human cells, however in multiple splice and translation variants that most likely differ between tissues and individuals [48] .”
BackgroundMineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628 · cited 1×
“, oxidised) locally in mineralocorticoid target tissues by the enzyme 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2) [29] .”
Background11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969 · cited 4×
“Furthermore, unbound cortisone circulates at concentrations similar to peak free cortisol, which provides a substrate for cortisol regeneration in peripheral tissues that express the enzyme 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) [46,47] .”
InfluentialTransdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954
Arlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency
Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411401 · Cited by 644
DHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566 · cited 1×
“No consistent association between DHEA(S) levels and subjective health status have been demonstrated in the elderly, and similarly no consistent benefit of DHEA replacement [111,112] .”
BackgroundLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 1×
“It has been estimated that the adrenals thus contribute with 30 – 50% of androgens in men and a very large proportion of androgens in women, particularly after menopause [104] .”
BackgroundNeurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Acute Hypothalamic–Pituitary–Adrenal Responses to the Stress of Treadmill Exercise
Luger, A., Deuster, P. A., Kyle, S. B., Gallucci, W. T., Montgomery, L. C., Gold, P. W., Loriaux, D. L., & Chrousos, G. P. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705213162105 · Cited by 516
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 1×
“Nevertheless, recent data indicate that mortality may be increased in Addison’s disease [4,20] , which has also been shown in secondary adrenal insufficiency [21] .”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 1×
“This gives rise to a diurnal and pulsatile cortisol release with high serum levels in the late night, and a gradual decline during the day [41,42] .”
BackgroundLong-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men
Orentreich, N., Brind, J. L., Vogelman, J. H., Andres, R., & Baldwin, H. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.4.1400863 · Cited by 417
Corticosteroid hormones in the central stress response: Quick-and-slow
de Kloet, E. R., Karst, H., & Joëls, M. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.10.002 · Cited by 391
Hunt, P. J., Gurnell, E. M., Huppert, F. A., Richards, C., Prevost, A. T., Wass, J. A. H., Herbert, J., & Chatterjee, V. K. K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7022 · Cited by 386 · cited 2×
“Several clinical trials of oral DHEA replacement therapy in Addison’s disease or secondary adrenal insufficiency, or both, have been published [13,119-122,124-127] .”
BackgroundLabrie, F., Bélanger, A., Cusan, L., & Candas, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4161 · Cited by 350
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 3×
“Furthermore, there is increasing evidence that such treatment confers higher risk of long-term adverse metabolic effects compared with the natural glucocorticoids [17,18,61,62] .”
BackgroundLabrie, F., Diamond, P., Cusan, L., Gomez, J.-L., Bélanger, A., & Candas, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.10.4306 · Cited by 292
Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement
Pratt, W. B., Galigniana, M. D., Harrell, J. M., & DeFranco, D. B. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.02.004 · Cited by 285 · cited 1×
“The GR resides in the cytoplasm in complexes with multiple chaperones, which serve to keep the GR in a conformation that enables glucocorticoid binding [50] and possibly modulate glucocorticoid sensitivity [51] .”
BackgroundHahner, S., Loeffler, M., Fassnacht, M., Weismann, D., Koschker, A.-C., Quinkler, M., Decker, O., Arlt, W., & Allolio, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0685 · Cited by 282
Mah, P. M., Jenkins, R. C., Rostami‐Hodjegan, A., Newell‐Price, J., Doane, A., Ibbotson, V., Tucker, G. T., & Ross, R. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02106.x · Cited by 243 · cited 2×
“3 Pharmacokinetics The cortisol levels after intake of hydrocortisone and cortisone acetate show large interindividual variation [53,54,66] .”
BackgroundKerrigan, J. R., Veldhuis, J. D., Leyo, S. A., Iranmanesh, A., & Rogol, A. D. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501158 · Cited by 228
Glucocorticoid replacement therapy: are patients over treated and does it matter?
Peacey, S. R., Guo, C., Robinson, A. M., Price, A., Giles, M. A., Eastell, R., & Weetman, A. P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.780907.x · Cited by 205
Arlt, W., Justl, H.-G., Callies, F., Reincke, M., Hübler, D., Oettel, M., Ernst, M., Schulte, H. M., & Allolio, B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4850 · Cited by 199
Purnell, J. Q., Brandon, D. D., Isabelle, L. M., Loriaux, D. L., & Samuels, M. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030440 · Cited by 199
Oelkers, W., Diederich, S., & Bähr, V (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.1.1320051 · Cited by 193 · cited 1×
“Plasma renin activity (PRA) or concentration has become widely used as effect parameters of mineralocorticoid action, with recommended target level at or slightly above the upper normal reference limit, as normalisation of PRA confers high risk of hypokalaemia, oedema and hypertension [33,35-38] .”
BackgroundLong-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial
Gurnell, E. M., Hunt, P. J., Curran, S. E., Conway, C. L., Pullenayegum, E. M., Huppert, F. A., Compston, J. E., Herbert, J., & Chatterjee, V. K. K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1134 · Cited by 189 · cited 5×
“, cardiovascular disease and osteoporosis [11-19] .”
BackgroundResultInfluentialJohannsson, G., Burman, P., Wirén, L., Engström, B. E., Nilsson, A. G., Ottosson, M., Jonsson, B., Bengtsson, B.-Å., & Karlsson, F. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8494 · Cited by 175
An assessment of optimal hydrocortisone replacement therapy
Howlett, T. A. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1340955.x · Cited by 169 · cited 5×
“Serum cortisol day curves have been advocated as the best objective measures of the glucocorticoid replacement [36,52,53,87] .”
BackgroundInfluentialDiederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W., & Bähr, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020970 · Cited by 154 · cited 2×
“Prednisolone is effectively inactivated by the placental 11 β -HSD [30] , and is probably of less concern during pregnancy.”
BackgroundLøvås, K., Gebre-Medhin, G., Trovik, T. S., Fougner, K. J., Uhlving, S., Nedrebø, B. G., Myking, O. L., Kämpe, O., & Husebye, E. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020769 · Cited by 144
Self-citationBright, G. M. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883829 · Cited by 137 · cited 1×
“The level of CBG may also influence the kinetics of cortisol directly by increasing the elimination time [68] .”
BackgroundAdrenocortical function in old age: response to acute adrenocorticotropin stimulation.
VERMEULEN, A., DESLYPERE, J. P., SCHELFHOUT, W., VERDONCK, L., & RUBENS, R. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-1-187 · Cited by 135
Veldhuis, J., & Pincus, S. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380358 · Cited by 92 · cited 1×
“, chaotic) [25] , which no therapy is able to mimic.”
BackgroundLongitudinal changes in dehydroepiandrosterone concentrations in men and women
Nafziger, A. N., Bowlin, S. J., Jenkins, P. L., & Pearson, T. A. (1998) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(98)90181-0 · Cited by 82
Plasma catecholamines in patients with Addison's disease
Bornstein, S. R., Breldert, M., Ehrhart‐Bornstein, M., Kloos, B., & Scherbaum, W. A. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01866.x · Cited by 70 · cited 1×
“However, the relative importance for patient functioning of unphysiological glucocorticoid and mineralocorticoid replacement, adrenal androgen depletion, adrenal medulla dysfunction [26,27] or the autoimmune disease per se is not known.”
BackgroundAgha, A., Liew, A., Finucane, F., Baker, L., O'Kelly, P., Tormey, W., & Thompson, C. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02035.x · Cited by 45
Laureti, S., Falorni, A., & Santeusanio, F. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345252 · Cited by 27
Adrenal Replacement Therapy: Time for an Inward Look to the Medulla?
Stewart, P. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1078 · Cited by 8 · cited 1×
“However, the relative importance for patient functioning of unphysiological glucocorticoid and mineralocorticoid replacement, adrenal androgen depletion, adrenal medulla dysfunction [26,27] or the autoimmune disease per se is not known.”
Background
Cited by
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
“Thus, as will be discussed further in Section VII, mimicking the circadian profile of cortisol blood levels may help to minimize side effects and increase the quality of life in patients with adrenal insufficiency (367, 368).”
Review: Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy
Chan, S., & Debono, M. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380214 · Cited by 243
Björnsdottir, S., Sundström, A., Ludvigsson, J. F., Blomqvist, P., Kämpe, O., & Bensing, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3561 · Cited by 70
Markovic, V. M., Cupic, Z., Vukojevic, V., & Kolar-Anic, L. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0037 · Cited by 54
Metadata
- Authors
- Løvås, K., & Husebye, E. S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-03-25
- Volume
- 17
- Issue
- 4
- Pages
- 497-509
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2156164215
- Cited by
- 32
- References
- 40
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.